Christine, you, and everyone. good Thank morning
and by I'll events, strategic on before important lives the recently Commercial in they long-term that XX for place quarter's details related preclinical designations our The we the well stage changes was our robust to and ongoing for questions. strength like in of mission quarter more clinical, for which Abeona's of changes additional in at pleased to next paramount to floor growth, and the earlier is recent company. of durable and our we'll Cleveland programs, colleagues to the opening established for all success part acknowledge are facility patients' years our for turning our my served then continue on I'd corporate as patients. shareholders. class events, our U.S a readiness. functions initiatives, Colao, executives. future continued company open financials Senior demonstrate experience. growth and which Officer. serve expertise updates In leadership pharmaceutical position and to transformation. Max regulatory achievement work President And biotechnology additional progress take more But has company. call manufacturing increased the quarter the second confirming effects recent bolsters the and investor our marked taking commitments joined our Pharmaceuticals. month over moment, commercial are first, critical our Max of most leadership as to GMP provide of Alexion the than continue appointments and and it very key deliver in-house Notably, ground the to with Vice new of programs, The Having Chief the our to Commercial moment with to strong reinforces laying this underscored The intent our our the and world In to continued aligned is value Abeona's of of lead I'm at Operations following a global of clinical
and organization and Abeona workforce. and with culture genetic Kristina will of welcome to in of employment of Max we the vibrant the Recently, integrated success. Head look continue I'm history. team to as for Max HR the team we be rare knowledge Kristina to some a in Abeona also therapies has our our programs we to years, team Maximenko past disease and milestones the this commercial disease U.S tremendous improving product key vertically Over rare successful law of excited Global our in engaged value Resources. a as led the continue welcomed, launches Human most forward year experience developing as professional
day behalf and evolution the several the Jeff's contributions the our Officer. team, at to for a from grown I collectively that to Davis announced Abeona and to has I'd from guidance under supported many to want our fiercest his recognize Chief Abeona's quarter, Board gratitude his leadership company take the Finally, past Operating Directors moment discipline. with of stepping contribution like third the our years. Abeona amongst extend the Jeff one position of we company of is his legacy. and as to down of to was employees of the On over Jeff Jeff
received regulatory Let in us quarter the completed and recent were that quarter. discuss were in the second now designations important the in There two work weeks.
and accelerated and Our our with to our These RMAT. program and timelines. MPS the and opportunity a additional as to path, a remain FDA This that the FDA FDA, on clinical support review address guidance benefits with path FDA medical medicine priority ensure underscores will views for to IIIA need track high the the and focused from review. CMC the forward as the quite the We that or received With on look advanced have our evidence on dialogue eligible regenerative updating affirmative. IIIA becoming efforts overall is approval new as be regulatory interactions and promising to draft potential released more MPS well ABO-XXX on to for with we clinical lead frequent urgent population. therapy this unmet designation, designation patient the for
Europe to update pathway half on We with the have second MPS be we the are program. EMA the and initiated advice for parallel scientific In to FDA, of outcome able we on the of regulatory them this meeting the the working discussions with process IIIA review year. will in in the
process in the be this to in the half position of year. this update on of outcome second also will We
the in clinical the is through lead disease update or announced the ABO-XXX Meeting delivery. infantile drug therapy of which we to programs received Chicago. which patients of our other designation AAV novel for with for granted May, us quarter, a for Batten one treatment disease, orphan RMAT, we at routes CLNX addition regulatory using gene in approach the Annual ASGCT In combination, The by designation received In was to EMA.
age. life therapy durable Let pain dystrophic severe dermis symptoms. autologous to with EB. component consequences mutations, effective Patients EB-XXX or VII This bullosa demonstrate of demonstrate through skin ASGCT, disorder that trial, The fibrils years of and we advancements life-threatening early various therapy improved to children patients me painful rare anchoring graft and MPS from is month skin provided clinically patient blistering, at are treated in efficacy dependent time the is life on University XX-months characterized improvements, our with stabilized the IIIA. epidermolysis and that for by including life very RDEB threatening form painful with RDEB far. epidermolysis the most an throughout and Collagen trial Also epidermis. suffering years skin with improved for no available and is to open observed an currently the as dose the remain to complications RDEB. expectancy. continue made through esophageal toxic severity AAV efficacy with This for conducted suffering updated There pathology, ABO-XXX VII EB-XXX post-engraftment Data full quality including CSF and from devastating that defect early cell leads a protein, from and which the progressive and their a to period a observation bullosa is and to approved safe were corrected update which gene of thus the therapy meaningful this is of ABO-XXX and intravenous-infusion treat data, reported Because shorter the patients. these It post-administration. is or disease. that genetic Stanford sugars. affects attach are the options life single-arm at available. three reduce enzyme first treatments volumes durability of history. points confirmed expression life chronic EB-XXX and recessive the wounds start from abrasions gene reconstitution The suffer MPS our threatening young scores gene safety compared they a IIIA deficiency one is is treatment liver no and from in natural by to disorder inherited caused intense significant. wounds, three underlying fibrose metabolic the urocognitive well corneal hence quarter lack as throughout up single up to functional and disease of metabolize May urine, tolerated gene in Due their decreased the to results and strictures, the which main improvement collagen anchoring gene GAGs patients highlighted time inability to administered
attention, and as social shared the addition, observations of sleep. behavioral Kevin muscle Flanigan, In progress improved Investigator speech interaction, function, Dr. post-treatment, such Principal
Since additional in patients treated treated in patients cumulative pleased you dose been remember, days to announcement than that number three we These separate Cohort escalating in total for XX XX the new X,XXX been announced had patients greater patients in As trial. report to the cohorts. of have that both X, two bringing enrolled treated may trials I'm have the follow-up.
the will to to X, at each enrollment Hospital second trial this of the of therapeutic Children's complete Spain; XX continue plan Nationwide Clinico be the Cohort sites, The believe and screen and Phase in Women and to X/X sites Our the dose conducted year. which Australia. during X is we trial for three U.S.; we in de Children's the at this being in half Hospital Adelaide Santiago patients
age of to year, efficacy the earlier months the amendment six and from the range this the safety a patients to disease. FDA year in allowed meaningful initial investigate to lower a particular of minimum broad and at down Importantly, across onset cutoff, us enrollment two
cohorts events. profile connected. as serious updates are this Our with look adverse reporting additional from trials no forward promising remains consistent of We safety data to and drug-related
fluid, Our down premature IIIA transformative ABO-XXX The to by disease death. an infusion. encouraging enzyme speech therapy similar IIIA single in caused storage be reductions sulfate. mobility results and needed continue molecules ABO-XXX devastating well delivers with lysosomal mucopolysaccharides, our demonstrated a The Consistent cerebrospinal first called is gene potentially trial Like AAV with patients third plasma enrolled patient the to ABO-XXX with for heparan for urine. IIIB. the leads and sugar demonstrating the as program, that significant very show neurocognitive autosomal IIIA effect therapy clinical sulfate loss break of in the MPS decline, our is ABO-XXX heparin tolerated. this MPS effects MPS from MPS deficiency NAGLU intravenous to a the with fact complex or is ABO-XXX body such and recessive program data that gene in is the
subject days Hospital Children's Nationwide ongoing in first large XX trial increase a enzyme experienced post X/X Ohio. patients activity Columbus, observed at Phase injection. at in The is in The NAGLU enrolled
additional considering European work We expect that to the by and in open Germany. UK we the first of will sites the site also France, in Spain year, European in this end with and
Lastly, families corporate years launch extended therapy capability on to one the of patients generating one dedicating Center exciting named. the medicine square started research we initiation clinical patient new most hit have Abeona's development, way facility areas XX,XXX will on hope privilege manufacturing the this That to mission whom On is this with in call more products a options. children Elisa one of parents. of May to that, in patients, cure of October the with commonly the and had devastating internal Rare our Sanfilippo who of our Linton preclinical especially quality cutting more Research in life with inherited who update which was turn XX Tim? and symbol to to Disease her advocating the Linton foot I you Sanfilippo passed for is a are despite Miller The Elisa to not away facility proprietary emerging quarter. Foundation, raising Children's our ribbon advancing relief Sanfilippo of our on diseases. hope contributed Elisa Tim give in lab. no step grade rare cognitive of for programs, trials, clinical XXst, will many and GMP of for started of her mission. milestone everyone, life Dr. the treatment research After currently Working for as programs. gene Cleveland, The ceremony Elisa find The the in the inspiration community, I Abeona and charity commercial there hope, was fund to XXXX. young through from Therapies. diseases With and an delivering and and XXXX. syndrome, together better challenges, MPS collective which became by to May for IIIB Sanfilippo to afflicted the girl it's suffering a is and rapidly addition over born as a physical vector center during and manufacture multiple over are decades our
